When AI designs a drug, who gets the credit?

MIT Technology Review reports that when the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI…

For Australian readers, the useful question is what this changes in everyday work: costs, productivity, privacy, hiring, or the tools businesses rely on. We are watching this story because practical AI adoption is moving quickly, and the impact often reaches workplaces before policy or training catches up.